Single-use technologies have become integral to modern biopharmaceutical manufacturing, supporting faster, more flexible production in an increasingly complex regulatory landscape. As adoption accelerates, the need for clear, consistent communication between end-users and suppliers has never been more critical. Yet effectively communicating single-use system (SUS) requirements remains a challenge across the industry, often revealing gaps in expectations between end-users and suppliers. 

We wanted to equip the industry with common tools to enable clear and consistent communication of user requirements and supplier capabilities in accordance with industry standards. BioPhorum, in collaboration with the BPSA, has therefore published an updated edition of the Single-Use User Requirements (SUUR) Toolkit – Implementation & Use. This update reflects both current regulatory expectations and the practical experience gained since its original release in 2019. 

The Toolkit is a collection of standard templates to support SUS design and qualification, facilitating right-first-time implementation. It includes a user requirements template, supply chain memo template and a supporting ‘how to’ and implementation guide. It equips the industry with common tools to enable clear and consistent communication of user requirements and supplier capabilities when building SUS for an end-user application. 

SUURs allow end-users to communicate process/application details and single-use requirements to suppliers, and allow suppliers to affirm or describe their capabilities to meet these requirements. The Toolkit uses consistent terminology in a logical structure of simple, categorized requirements. 

The supply chain memo template is an additional, optional template that allows end-users to communicate requests for supply-chain-related information at the component level to suppliers, providing transparency of the supply chain for a SUS and enabling understanding and management of risk.  

So what is new and why does it matter? 

  • The updated guidance is now aligned with ASTM E3051-25, EU GMP Annex 1 and BPSA Quality Test Matrices 
  • It contains practical, step-by-step recommendations for implementing SUURs across organizations and supply chains 
  • It has an expanded focus on cross-functional engagement between manufacturing, quality, engineering, sourcing and suppliers 
  • It contains clear guidance on how to use the SUUR template and optional supply chain memo to improve transparency, reduce rework and accelerate ‘right first time’ execution 
  • It includes real-world considerations for rollout, governance and change management. 

The SUUR Toolkit adds significant value to the industry by establishing a common language and a structured approach for defining requirements and confirming supplier capabilities. This reduces misalignment, mitigates risk and supports faster, more robust implementations of SUS. 

For end-users, the Toolkit minimizes non-conformances and regulatory risks caused by gaps in expectations with suppliers. It also reduces implementation timelines for new designs, minimizes supply disruptions, and facilitates second sourcing by comparing supplier responses like-for-like. 

For suppliers, the Toolkit deepens the understanding of customer application and requirements up front, ensuring that designs are fit for use. It also provides consistency in the content and format of user requirements, reducing the time and resources required to respond by preparing standard responses in advance. 

Developed collaboratively by end-users and suppliers, this update reinforces SUURs as a foundational best practice for designing, qualifying and implementing SUS in today’s regulatory and supply-constrained environment, and will help drive consistency, transparency and confidence across SUS design and supply. 

Click here to download the new SingleUse User Requirements (SUUR) Toolkit – Implementation & Use 

December 17, 2025, (ARLINGTON, VA) – The Bio-Process Systems Alliance (BPSA) is pleased to announce the publication of its latest technical resource, Automation of Single-Use Unit Operations in Bioprocessing: Traps, Tips & Trends.   

Automation in bioprocessing—especially for single-use systems—can boost efficiency and consistency, enable real-time control, and support flexible and scalable manufacturing. This comprehensive white paper provides practical guidance for suppliers and end-users of single-use systems integrating automation into single-use bioprocesses. The document presents the perspective of two personas with different backgrounds in automation and single-use technologies, and addresses key topics including:  

-Fundamentals of automation and control strategies for single-use systems
-Common pitfalls and best practices for implementation
-Real-world examples of highly automated bioprocessing facilities
-Insights on digital communication and data integrity  

Developed by the BPSA Automation Committee, this white paper aims to bridge the knowledge gap between automation engineers and single-use technology specialists. It is designed to help companies improve efficiency, reduce risk, and accelerate innovation in bioprocessing.  

“This white paper represents a significant step forward in helping our industry automate systems and processes, enabling us to get important, life-saving products to our customers, patients and consumers faster. I especially want to thank the two co-chairs of the BPSA Automation Committee, Stuart Tindal, EngD, PhD of Sartorius, and Hernan Parma of Renolit Healthcare, for their leadership,” said Chris Clark, BPSA Executive Director. “I also want to thank and congratulate the broader BPSA Automation Committee for their dedication and collaboration in producing this important BPSA resource.”

The white paper is now available for download at: https://www2.bpsalliance.org/forms/store/ProductFormPublic/automation-of-single-use-unit-operations-in-bioprocessing-traps-tips-and-trends    

About BPSA 
The Bio-Process Systems Alliance (BPSA) is an industry-led trade association dedicated to advancing the adoption and implementation of single-use technologies in biopharmaceutical manufacturing. For more information, visit www.bpsalliance.org.     

Contact:
Christopher Clark
Executive Director
571-348-5109
cclark@socma.org
October 29, 2025 (Arlington, VA) – The Bio-Process Systems Alliance (BPSA), the international association for the single-use bioprocessing industry, has announced the host cities for its International Single‑Use Summits in 2026 and 2027:  

2026 Summit: July 27–29, Fairmont Copley Plaza, Boston, MA

2027 Summit: July 12-14, Fairmont Washington, DC Georgetown, Washington, DC

The annual BPSA International Single-Use Summit is the premier event for the single-use bioprocessing community, bringing together suppliers, end users, pharmaceutical and biotech professionals, regulators and key industry partners. The Summit features technical committee workstreams, educational sessions, expert panel discussions, and networking opportunities, all designed to drive innovation and collaboration across the industry.  

“We’re excited to bring our Summit to Boston in 2026, marking the first time BPSA has hosted the Summit outside of Washington, DC,” said Chris Clark, Executive Director of BPSA. “These locations were selected based on member and attendee feedback. Boston is a leading global hub for biotechnology innovation, while Washington, DC keeps us closely connected to regulatory agencies and policy leaders. Both venues will help us foster collaboration and expand our reach across the global single-use bioprocessing ecosystem.”   

To learn more about the annual BPSA Summit and view program highlights from the 2025 event, visit bpsalliance.org.    

About BPSA:  An affiliate of SOCMA, The Bio-Process Systems Alliance (BPSA), is an industry-led association dedicated to encouraging and accelerating the adoption of single-use manufacturing technologies used in the production of biopharmaceuticals and vaccines. BPSA facilitates education, best practice sharing, and networking opportunities among its member companies. For more information, visit www.bpsalliance.org.     

Contact:
Tatiana Letcheva
Director
571-348-5100
tletcheva@socma.org      

Arlington, VA – The Bio-Process Systems Alliance (BPSA) has released the next five Frequently Asked Questions (#6–10) on Single-Use Systems (SUS) for Integrity Assurance. Developed by BPSA’s Integrity Assurance Committee, these FAQs address key industry concerns related to the integrity and testing of single-use systems and components. They are designed to assist both manufacturers and end-users in maintaining the integrity of SUS throughout the bioprocessing lifecycle.

The newly released FAQs include:

  • Do I have to perform an integrity test at the point of use (POU)?
  • Is there a difference between testing at the end-user site and testing at the SUS supplier’s manufacturing site?
  • When is it appropriate to perform a POU leak test vs. a POU integrity test?
  • Should integrity testing be performed at every stage of biologics manufacturing?
  • What information should suppliers provide to support the use of assemblies in sterile product manufacturing?

BPSA published the Design, Control, and Monitoring of Single-Use Systems for Integrity Assurance in 2017, that offered recommendations for both suppliers and end-users on strategies, tools, and procedures to enhance integrity assurance. In 2023, BPSA released Design, Control & Monitoring of SUS for Integrity Assurance: Volume 2 as a follow-up to the 2017 guide. View BPSA’s library of technical industry resources here.

“We would like to express our appreciation to the BPSA Integrity Assurance Committee and its Chair, Patrick Evrard of Cytiva, for their guidance and insight in preparing these FAQs,” said BPSA Executive Director Chris Clark. “These resources play an important role in helping companies strengthen the reliability of their single-use systems.”

Submit Your Questions:

If you have additional questions about SUS integrity assurance, you can submit them to bpsa@socma.org. All inquiries will be reviewed by BPSA’s Integrity Assurance Committee, and the most relevant questions will be added to the list of FAQs as the resource is updated.

For more information about BPSA industry resources or joining the BPSA member network and technical committees, visit the BPSA website or contact us at bpsa@socma.org.

About BPSA 

The Bio-Process Systems Alliance (BPSA), an affiliate of SOCMA, was formed in 2005 as an industry-led international industry association dedicated to encouraging and accelerating the adoption of single-use manufacturing technologies used in the production of biopharmaceuticals and vaccines. www.bpsalliance.org

The Bio-Process Systems Alliance (BPSA) is pleased to announce the release of a new one-pager that highlights the critical role of Single-Use Technologies (SUTs) in advancing sustainability and innovation in bioprocessing.  

BPSA’s one-pager outlines the numerous benefits of SUTs:

Reducing resource consumption – lowering water, chemical, and energy usage
Minimizing environmental impact – generating low levels of plastic waste
Accelerating healthcare advancements – enabling faster vaccine and drug production
Driving continuous innovation – enhancing efficiency, recycling, and eco-design  

Access the full resource and references by scanning the QR code on the document.  

Download the new one-pager today and share it with your colleagues, customers, and networks. Learn more and join us in driving sustainable solutions in single-use bioprocessing!    

This resource was developed by BPSA’s Sustainability Committee. Learn more about BPSA’s committees and technical resources.  

Arlington, VA– The Bio-Process Systems Alliance (BPSA), the international association for the single-use bioprocessing industry, has announced its newly elected Board members for 2025–2026, following the December 5th Board meeting.

Mark Petrich, PhD, Vice President, Process Development & Validation, Krystal Biotech, Inc., was re-elected as Chair for a second two-year term, and Todd Kapp, CEO of Business Development at Wautoma Biotech LLC, was re-elected as First Vice Chair.

Brendan Lucey, Cross Business Unit Director of Marketing Strategy-Life Sciences, Entegris, Inc., and Ping Wang, PhD, Director, Material Sciences, Therapeutics Development & Supply (TDS), Discovery, Product Development & Supply, Johnson & Johnson Innovative Medicine, were elected to two-year terms as Directors at-large.

Lucey oversees the go-to-market strategy for Life Sciences at Entegris. He has previously served on the BPSA Board and currently chairs the BPSA Cell and Gene Therapy Committee. A biologist by training, he previously held positions at CDMOd, Lonza, Sartorius, ILC Dover and Gemini Bio.

Wang serves as a Scientific Director at Johnson & Johnson Innovative Medicine, responsible for the selection, qualification and investigation of single-use materials used for the J&J large molecules R&D and manufacturing network. Within BPSA, Ping is actively engaged in the BPSA Cell & Gene Therapy, End-user Committee and X-ray Sterilization Committees. Ping earned a PhD from the College of Pharmacy at University of Georgia, an MBA from Drexel University, and MS and BS degrees from Peking University.

Patrick Evrard, Quality Assurance/Regulatory Affairs, Cytiva; Charlott Masy, PhD, Senior Manager, GSK; Ralph Daumke, Market Manager EMEA, PendoTECH; Hernán Parma, Head of Sales-America, RENOLIT Healthcare and Stuart Tindal, EngD., PhD, Product Manager, Sartorius, were also re-elected as Directors-at-Large for two-year (2025-2026) terms.

“I extend my congratulations to Mark and Todd on their re-election as Chair and First Vice Chair,” said BPSA Executive Director Chris Clark. “As BPSA enters its 20th year, their extensive experience and leadership will be critical in guiding the Alliance as we move forward. I also congratulate our new and returning Board members and thank all our dedicated volunteer leaders for their time, expertise, and commitment to advancing BPSA’s mission.” Clark added, “A special thanks to Matt Sitcoske of High Purity New England and Danielle Arcuri of Qosina Corporation for their invaluable contributions as Directors-at-Large as their terms conclude this year.”

BPSA Executive Board Officers:

  • Chair: Mark Petrich, PhD, Krystal Biotech
  • 1st Vice Chair: Todd Kapp, Wautoma Biotech, LLC
  • 2nd Vice Chair: Kirsten Strahlendorf, Sanofi
  • Secretary: Todd Andrews, CPC
  • Treasurer: Ravi Narayanan, Dupont

At-Large Directors (newly elected) through 2026:

  • Brendan Lucey, Entegris
  • Ping Wang, PhD, Johnson & Johnson

At-Large Directors continuing through 2025 and/or 2026: 

  • Monica Cardona, Millipore Sigma
  • Brian Chung, Syensqo
  • Ralph Daumke, PendoTECH
  • Patrick Evrard, Cytiva
  • Jayanthi Grebin, Freudenberg Medical
  • Dianne Heiler, Repligen Corporation
  • Charlotte Masy, PhD, GSK
  • Hernán Parma, RENOLIT Healthcare
  • John Puglia, PhD, Thermo Fisher Scientific
  • Stuart Tindal, EngD, PhD, Sartorius
  • Thomas Vandromme, Meissner
  • Chris Wilkins, PhD, Filtration Group

Board members are elected by BPSA’s general membership to serve staggered two-year terms. They establish governing policies, determine budget priorities, and set strategic goals to advance the organization and its mission of supporting the single-use bioprocessing industry globally.

Please visit https://bpsalliance.org/about/board-of-directors/ for a complete list of BPSA Board of Directors.

About BPSA

An affiliate of SOCMA, the Bio-Process Systems Alliance, is an industry-led association dedicated to encouraging and accelerating the adoption of single-use manufacturing technologies used in the production of biopharmaceuticals and vaccines. BPSA facilitates education, best practice sharing, development of consensus guides and networking opportunities among its member companies. For more information, visit www.bpsalliance.org.

Arlington, VA – The Bio-Process Systems Alliance (BPSA) is pleased to announce the release of a new FAQ resource on the integrity assurance of single-use systems (SUS). These FAQs, developed by BPSA’s Integrity Assurance Committee, address common industry questions about the integrity and testing of single-use systems and components. They are designed to assist both manufacturers and end-users in ensuring the integrity of their single-use systems throughout the bioprocessing lifecycle.

Key FAQs Include:

  • Is it possible to perform a leak/integrity test on SUS post-use?
  • Why is it often recommended to use a porous spacer when testing SUS in its container?
  • Does the compressed air used to perform a leak/integrity test at the supplier(s)’ site need to be filtered?
  • Will the leak/integrity test damage my SUS product?
  • What is the difference between a leak test and an integrity test?

These integrity assurance FAQs are the first in a series of FAQs and will be updated as needed by BPSA. In addition to these FAQs, BPSA offers comprehensive technical guides on SUS integrity assurance in its industry resources library. In 2017, BPSA published the Design, Control, and Monitoring of Single-Use Systems for Integrity Assurance, which provided recommendations for both suppliers and end-users regarding strategies, tools, and procedures to enhance the integrity assurance of single-use systems. In 2023, BPSA published Design, Control & Monitoring of SUS for Integrity Assurance: Volume 2, as a follow-up to the 2017 guide.

These resources are essential tools for companies looking to enhance the reliability and safety of their single-use technologies. “I want to thank the BPSA Integrity Assurance Committee, and its Chair, Patrick Evrard of Cytiva, for their leadership and hard work in developing these FAQs,” said BPSA Executive Director, Chris Clark. “SUS Integrity has always been a crucial quality attribute for suppliers, end-users, and regulatory authorities, and the new Annex 1 makes it even more critical.  These FAQs will play a key role in advancing both the use and integrity of single-use systems.”

Submit Your Questions:

If you have additional questions about SUS integrity assurance, you can submit them to bpsa@socma.org. All inquiries will be reviewed by BPSA’s Integrity Assurance Committee, and the most relevant questions will be added to the list of FAQs as the resource is updated.

For more information about BPSA industry resources or joining the BPSA member network and technical committees, visit the BPSA website or contact us at bpsa@socma.org.

About BPSA

The Bio-Process Systems Alliance (BPSA), an affiliate of SOCMA, was formed in 2005 as an industry-led international industry association dedicated to encouraging and accelerating the adoption of single-use manufacturing technologies used in the production of biopharmaceuticals and vaccines. www.bpsalliance.org.

Join BPSA for its 2024 International Single-Use Summit on July 22-24, at the Four Seasons Hotel in Washington, DC! BPSA’s annual Summit is the premier business and networking conference for users and suppliers in the single-use technology industry.

3 Reasons to Attend the BPSA Summit

1.Latest Industry Insights

The comprehensive two-and-a-half-day program will feature presentations from thought leaders and global industry experts on key issues and trends impacting the single-use eco-system.

Session topics include:
Economic Outlook for the Single-Use Industry
Advancing Sustainability in Single-Use
Manufacturing Capacity and Supply Chain Continuity
Navigating Key Global Regulatory Developments
Digitalization and the Role of AI in BioprocessingAnd More!

Check out the agenda at a glance for more details.

2.Industry Collaboration

Engage in dialogue and collaboration with industry experts. In addition to our program of education sessions and discussion panels, BPSA members are encouraged to attend and participate in BPSA’s technical committee meetings.

BPSA Committees include:
Automation Committee
Cell and Gene Therapy Committee
Continuous Bioprocessing Committee
Integrity Assurance Committee
Sustainability Committee
X-Ray Committee

Learn more about BPSA’s technical committees here.

3.Networking Opportunities

The BPSA Summit brings together over a hundred attendees, including suppliers, end-users, educators, regulators and industry partners! Learn more about BPSA members here and our network of 70+ companies worldwide.

Join us for the BPSA Summit Welcome Reception on Monday, July 22, at the Four Seasons Hotel, sponsored by Burkert, and kick-off your networking with additional networking opportunities throughout the event!

A special thanks to our Summit reception sponsor:

Source: Bioprocess Online

Single-Use Technologies For Bioprocessing: An Essential Update

Mark Petrich, VP of Technical Operations, Krystal Biotech and Chairman, BioProcess Systems Alliance (BPSA) and Single-Use Expert Consultant, Scientific Advisory Council Member at Bio-Process Systems Alliance (BPSA), and ASME (The American Society of Mechanical Engineers) BPE Single-Use Subcommittee member Paul Priebe joined Bioprocess Online Live host, Matt Pillar, for Single-Use Technologies for Bioprocessing: An Essential Update. During this digital event, they covered the latest in standardization efforts around single-use in biopharma, regulatory considerations, single-use applications, supply security strategies, single-use economics, and more.

Click here to learn more and to access recording.

ARLINGTON, VA – The Bio-Process Systems Alliance (BPSA), the international association of the single-use bio-processing industry, announced it expanded its Board of Directors to 19 members to lead the organization in 2024/2025 during its recent election.

Kirsten Strahlendorf, M.Eng., P.Eng., PMP, Senior Unit Head, BioProcess Engineering Unit, Sanofi, has been elected Second Vice Chair; Todd Andrews, Director Application and Business Development, Biopharma, CPC, has been re-elected Secretary, and Ravi Narayanan, Global Product Management Leadership-Biopharma & Medical Device, Nordson Medical has been re-elected Treasurer. Also, Chris Wilkins, PhD, Vice President, Strategic Marketing, Filtration Group; Jayanthi Grebin, Business Development Manager Pharmaceuticals NA, Freudenberg Medical; Thomas Vandromme, Business Development Director, Meissner; Monica Cardona, Global Senior Marketing Manager Single Use Systems, Millipore Sigma; Dianne Heiler, Global Head of Packaging Engineering and Sustainability, Repligen Corporation; Brian Chung, Senior Key Account Manager, Specialty Polymers, Solvay and John Puglia, PhD, Senior Director, Global R&D, Thermo Fisher Scientific were elected as Directors-at-Large.

“Congratulations to Kirsten, Todd and Ravi on being elected to the BPSA Executive Board and congratulations to our new and returning BPSA Board members,” said Mark Petrich of Krystal Biotech, BPSA Chair. “I want to thank each of our dedicated volunteer leaders who have chosen to contribute their time and expertise to the BPSA Board. I look forward to working together to advance the mission of BPSA. I would like to express my appreciation to Dan Rosen, Vice President & General Manager, Thermo Fisher Scientific and Scott Patterson, Vice President Pharma & Biotech Technical Support, ILC Dover, whose terms as Directors-at-Large are ending this year.”

BPSA Executive Board Officers:

  • Chair: Mark Petrich, PhD, Krystal Biotech
  • 1st Vice Chair: Todd Kapp, Entegris, Inc.
  • 2nd Vice Chair: Kirsten Strahlendorf, Sanofi
  • Secretary: Todd Andrews, CPC
  • Treasurer: Ravi Narayanan, Nordson Medical

At-Large Directors (newly elected) through 2025:

  • Chris Wilkins, PhD, Filtration Group
  • Jayanthi Grebin, Freudenberg Medical
  • Thomas Vandromme, Meissner
  • Dianne Heiler, Repligen Corporation
  • John Puglia, PhD, Thermo Fisher Scientific  

At-Large Directors continuing through 2024/2025:

  • Patrick Evrard, Cytiva
  • Charlotte Masy, GSK
  • Mark Sitcoske, High Purity New England
  • Monica Cardona, Millipore Sigma
  • Ralph Daumke, PendoTECH
  • Danielle Arcuri, Qosina Corporation
  • Hernán Parma, RENOLIT Healthcare
  • Elisabeth Vachette, Sartorius
  • Brian Chung, Solvay

Board members are elected by the general membership and serve staggered two-year terms. The Board determines the governing policies of BPSA, establishes the budget and priorities, and directs the organization’s goals and priority areas of focus.

Please visit https://bpsalliance.org/about/board-of-directors/ for a complete list of BPSA Board of Directors.

The Bio-Process Systems Alliance (BPSA), is an industry-led association dedicated to encouraging and accelerating the adoption of single-use manufacturing technologies used in the production of biopharmaceuticals and vaccines. BPSA facilitates education, best practice sharing, development of consensus guides and networking opportunities among its member companies. For more information, visit www.bpsalliance.org, or contact Executive Director Chris Clark at cclark@socma.org.